(Q38196747)

English

The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis

scientific article published on 18 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

0 references

1 reference

Europe PubMed Central

The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

based on heuristic

inferred from title

author name string

Xia Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Qian Xiao

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Li Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Qiao Yang

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Xiaoyan Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Lingjie Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Wen Cheng

7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

18 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Pharmacoepidemiology and Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

687-698

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3586

21 January 2018

Identifiers

10.1002/PDS.3586

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38196747&oldid=2094978958"